Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial

BACKGROUND: The aim of this study was to evaluate the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy following first-line FOLFIRINOX treatment failure in advanced pancreatic cancer. METHODS: This was a multicenter, single-arm, open-label, phase 2 trial done...

Descripción completa

Detalles Bibliográficos
Autores principales: Huh, Gunn, Lee, Hee Seung, Choi, Jin Ho, Lee, Sang Hyub, Paik, Woo Hyun, Ryu, Ji Kon, Kim, Yong-Tae, Bang, Seungmin, Lee, Eaum Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591648/
https://www.ncbi.nlm.nih.gov/pubmed/34790261
http://dx.doi.org/10.1177/17588359211056179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591648/
https://www.ncbi.nlm.nih.gov/pubmed/34790261
http://dx.doi.org/10.1177/17588359211056179

Ejemplares similares